Sustained Inhibition of Receptor Tyrosine Kinases and Macrophage Depletion by PLX3397 and Rapamycin as a Potential New Approach for the Treatment of MPNSTs
PATWARDHAN, Parag P, SURRIGA, Oliver, BECKMAN, Michael J, DE STANCHINA, Elisa, DEMATTEO, Ronald P, TAP, William D, SCHWARTZ, Gary K
Published in Clinical cancer research (15.06.2014)
Published in Clinical cancer research (15.06.2014)
Get full text
Journal Article
Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma
Patwardhan, Parag P, Ivy, Kathryn S, Musi, Elgilda, de Stanchina, Elisa, Schwartz, Gary K
Published in Oncotarget (26.01.2016)
Published in Oncotarget (26.01.2016)
Get full text
Journal Article
MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma
Slotkin, Emily K, Patwardhan, Parag P, Vasudeva, Shyamprasad D, de Stanchina, Elisa, Tap, William D, Schwartz, Gary K
Published in Molecular cancer therapeutics (01.02.2015)
Published in Molecular cancer therapeutics (01.02.2015)
Get full text
Journal Article
Abstract 4450: CB839, an orally bioavailable glutaminase inhibitor, shows potent antitumor activity in vitro against models of soft tissue sarcoma and chondrosarcoma
Sheikh, Tahir N., Patwardhan, Parag P., Cremers, Serge, Schwartz, Gary K.
Published in Cancer research (Chicago, Ill.) (01.08.2015)
Published in Cancer research (Chicago, Ill.) (01.08.2015)
Get full text
Journal Article
Abstract 4526: BIBF1120, an investigational triple angiokinase inhibitor, in combination with inhibitors of mTOR signaling shows potent antitumor activity in preclinical models of sarcoma
Patwardhan, Parag P., Musi, Elgilda, Ivy, Kathryn S., Giovino, Natalie, Schwartz, Gary K.
Published in Cancer research (Chicago, Ill.) (01.10.2014)
Published in Cancer research (Chicago, Ill.) (01.10.2014)
Get full text
Journal Article